Orchard Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016
Net Income	-150.66	-144.58	-151.98	-163.42	-230.5	-39.74	-19.09
Depreciation & Amortization	2.74	2.33	2	1.68	1.2	0.3	0.01
Share-Based Compensation	16.01	22.54	27.96	19.42	6.77	1.02	0.2
Other Operating Activities	55.92	-5.38	-4.26	-23.81	124.99	5.94	4.31
Operating Cash Flow	-75.99	-125.1	-126.27	-166.13	-97.54	-32.49	-14.57
Capital Expenditures	1.45	-2.13	-10.79	-4.37	-4.03	-1.56	-0.19
Change in Investments	89.11	-29.15	168.17	-304.99	0	0	0
Other Investing Activities	-	-0.89	-	-	-	-	-
Investing Cash Flow	90.56	-32.17	157.38	-309.36	-4.03	-1.56	-0.19
Share Issuance / Repurchase	0.21	157.44	3.94	133.59	209.7	0	0
Debt Issued / Paid	-0.79	7.38	0	24.47	0	0	0
Other Financing Activities	-0.12	-6.75	-	-0.61	145.17	115.7	18.03
Financing Cash Flow	-0.69	158.07	3.94	157.45	354.86	115.7	18.03
Exchange Rate Effect	-1.42	-0.03	1.04	1.67	-3.47	4.71	-0.75
Net Cash Flow	12.46	0.78	36.08	-316.36	249.83	86.36	2.53
Free Cash Flow	-74.54	-127.23	-137.07	-170.5	-101.57	-34.05	-14.76
Free Cash Flow Margin	-329.00%	-7595.76%	-5281.93%	-6784.64%	-4892.49%	-	-
Free Cash Flow Per Share	-5.82	-10.26	-13.78	-18.29	-45.02	-38.37	-20.78

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).